TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which...
Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at...
